Integración de ascorbato de sodio intravenoso y Medicina Biorreguladora de Sistemas como soporte durante el tratamiento.
Year: 2026
Type: preprint
Study design: Case Report
Abstract: Background: Clinical evidence supporting the use of intravenous sodium ascorbate and bioregulatory systems medicine as supportive care during chemotherapy is limited. We report the case of a patient with two synchronous primary malignancies who received conventional oncological treatment and complementary supportive care.Case presentation: A 74-year-old woman was diagnosed with right-sided triple-negative breast carcinoma, initially staged as cT2N0M0, and endometrial serous carcinoma. She received four cycles of neoadjuvant doxorubicin and cyclophosphamide, followed by right mastectomy with axillary lymph node dissection and gynecologic oncological surgery. She subsequently completed six cycles of adjuvant paclitaxel and carboplatin. During treatment, she received intravenous sodium ascorbate and bioregulatory systems medicine preparations as complementary supportive care, without replacing antineoplastic treatment. She completed all 10 planned cycles, with no documented dose reductions, and maintained an ECOG performance status of 0 and a Karnofsky performance status of 90–100%. Nonhematologic adverse events were predominantly grade 1. Before the third neoadjuvant cycle, laboratory testing revealed grade 4 neutropenia, with an absolute neutrophil count of 290/µL and subsequent recovery, without documented febrile neutropenia or serious infection. The maximum diameter of the breast lesion decreased from 33 to 12 mm, and endometrial thickness decreased from 20 to 6 mm; however, histopathological examination confirmed residual disease at both sites. At the most recent clinical assessment, there was no clinical evidence of active malignancy or ongoing toxicity.Conclusion: The incorporation of intravenous sodium ascorbate and bioregulatory systems medicine as complementary supportive care was feasible and occurred alongside treatment completion, predominantly favorable clinical tolerability, and preservation of functional status. However, the single-case design, absence of a comparator group, and concurrent use of other supportive measures preclude attributing the observed treatment continuity, reduction in toxicity, or tumor response to these interventions. These findings warrant further evaluation in prospective controlled studies.
Source: Figshare
Authors: Carmen Rivas, Paula Martinez, LUIS MARTINEZ
Language: English
Subfield: Nutrition and Dietetics
Field: Nursing
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W7225996200
